Literature DB >> 7252542

Serum prolactin in patients with hypothalamus and pituitary disorders.

P O Lundberg, P O Osterman, L Wide.   

Abstract

Serum prolactin concentrations were studied in 115 patients with anatomically defined disorders in the hypothalamo-pituitary region. Fifty of the patients had expansively growing pituitary adenomas; in 17 of them (13 females and four males) the prolactin values were slightly raised (15 to 100 microgram/liter), and in 13 (11 females and two males) they were over 100 microgram/liter. The frequency of elevated prolactin values was higher for females than for males. Fifteen patients with invasively growing pituitary adenomas had very high serum prolactin levels (range 1230 to 31,500 microgram/liter). In a single case of malignant pituitary adenoma, the serum prolactin was at the lower level of detection. Of 49 further patients with suprasellar meningiomas, craniopharyngiomas, or other expansive or destructive lesions of the hypothalamus and sellar region, 15 had slightly raised prolactin values (maximum 114 microgram/liter). Eight of these 49 patients had sellar destruction, with a roentgenological picture similar to that in patients with invasive pituitary adenomas. Among these eight patients, the maximum prolactin value was 67 microgram/liter. It is concluded that moderately raised serum prolactin values (up to 100 microgram/liter) in a patient with a sellar tumor does not prove that the tumor is a prolactinoma. A serum prolactin value of 100 to 1000 microgram/liter strongly indicates a prolactin-producing tumor. In a patient with sellar destruction, a serum prolactin value of over 1000 microgram/liter is proof that the destruction is caused by an invasive pituitary adenoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252542     DOI: 10.3171/jns.1981.55.2.0194

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Non-Hodgkin lymphoma with panhypopituitarism, hyperprolactinaemia and sixth nerve palsy.

Authors:  J A Shaw; F M Strachan; H A Sawers; J S Bevan
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

3.  Prolactinoma coexistent with granulomatous hypophysitis.

Authors:  S Holck; H Laursen
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

4.  Treatment of craniopharyngiomas--the stereotactic approach in a ten to twenty-three years' perspective. II. Psychosocial situation and pituitary function.

Authors:  M Sääf; M Thorén; C G Bergstrand; G Norén; T Rähn; L Tallstedt; E O Backlund
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

5.  Craniopharyngioma with hyperprolactinaemia due to a prolactinoma.

Authors:  T Wheatley; J D Clark; S Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

Review 6.  Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.

Authors:  Pedro Iglesias; Víctor Rodríguez Berrocal; Juan José Díez
Journal:  Endocrine       Date:  2018-06-16       Impact factor: 3.633

7.  Invasive pituitary oncocytoma.

Authors:  M I Okoye; W F Mueller
Journal:  J Natl Med Assoc       Date:  1983-12       Impact factor: 1.798

8.  Clinical Features, Therapeutic Trends, and Outcome of Giant Prolactinomas: A Single-Center Experience Over a 12-Year Period.

Authors:  Mussa H Almalki; Naji Aljohani; Saad Alzahrani; Ohoud Almohareb; Maswood M Ahmad; Abdullah A Alrashed; Fahad Alshahrani; Badurudeen Mahmood Buhary
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.